These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20827162)

  • 21. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.
    Charpentier C; Piketty C; Laureillard D; Tisserand P; Si-Mohamed A; Weiss L; Bélec L
    Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):129-33. PubMed ID: 21559766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
    Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
    PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
    Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
    AIDS; 2017 Jul; 31(11):1529-1534. PubMed ID: 28463882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
    J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raltegravir: in treatment-naive patients with HIV-1 infection.
    Croxtall JD; Scott LJ
    Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.
    Wang X; Mink G; Lin D; Song X; Rong L
    J Theor Biol; 2017 Mar; 416():16-27. PubMed ID: 28025011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
    Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
    J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.
    Poizot-Martin I; Faucher O; Obry-Roguet V; Nicolino-Brunet C; Ronot-Bregigeon S; Dignat-George F; Tamalet C
    J Clin Virol; 2013 Aug; 57(4):351-5. PubMed ID: 23664725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
    Funderburg NT; Andrade A; Chan ES; Rosenkranz SL; Lu D; Clagett B; Pilch-Cooper HA; Rodriguez B; Feinberg J; Daar E; Mellors J; Kuritzkes D; Jacobson JM; Lederman MM
    PLoS One; 2013; 8(12):e83514. PubMed ID: 24367599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
    Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
    Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
    Weber MD; Andrews E; Prince HA; Sykes C; Rosen EP; Bay C; Shaheen NJ; Madanick RD; Dellon ES; De Paris K; Nelson JA; Gay CL; Kashuba AD
    Antivir Ther; 2018; 23(6):495-504. PubMed ID: 29714167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
    Lee SA; Telwatte S; Hatano H; Kashuba ADM; Cottrell ML; Hoh R; Liegler TJ; Stephenson S; Somsouk M; Hunt PW; Deeks SG; Yukl S; Savic RM
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):530-537. PubMed ID: 32168200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
    Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
    Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
    Front Immunol; 2018; 9():811. PubMed ID: 29760693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.